Bimatoprost
Pronouncation: (bye-MAT-oh-proste)Class: Prostaglandin agonist
Trade Names:
Lumigan
- Solution 0.03%
Pharmacology
 | |||||||||
Feedback for Bimatoprost
Compare with other drugs.
| |||||||||
May lower IOP by increasing outflow of aqueous humor through the trabecular meshwork and uveoscleral routes.
Indications and Usage
Reduction of IOP in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering agents or insufficiently responsive to other IOP-lowering medications.
Contraindications
Standard considerations.
Dosage and Administration
AdultsOphthalmic Instill 1 drop in affected eye(s) in evening.
Storage/Stability
Store at controlled room temperature (59° to 77°F). Keep container tightly closed.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Headache.
Dermatologic
Hirsutism.
EENT
Conjunctival hyperemia; eyelash growth; ocular pruritus; ocular dryness; visual disturbances; ocular burning; foreign body sensation; eye pain; pigmentation of the periocular skin; blepharitis; cataract; superficial punctate dermatitis; eyelid erythema; ocular irritation; eyelash darkening; eye discharge; tearing; photophobia; allergic conjunctivitis; asthenopia; increase in iris pigmentation; conjunctival edema.
Hepatic
Abnormal LFTs.
Respiratory
Upper respiratory infections.
Miscellaneous
Cold; asthenia.
Precautions
MonitorEnsure that IOP has been measured and documented in the patient's record. |
Pregnancy
Category C .
Lactation
Undetermined.
Children
Safety and efficacy not established.
Active intraocular inflammation
Use with caution in patients with iritis/uveitis.
Bacterial keratitis
Bacterial keratitis has been reported with multiple-dose containers as a result of patient contamination.
Contact lenses
Remove contact lenses prior to and do not wear for 15 min following administration.
Macular edema
Use with caution in aphakic patients, pseudophakic patients with a risk of torn posterior lens capsule, or in patients with risk factors for macular edema.
Pigmentation changes
Permanent changes to pigmented tissue may occur, most frequently involving pigmentation of the iris and eyelid and increased pigmentation and growth of eyelashes. Gradual change in eye color (ie, increased amount of brown pigmentation in the iris) may occur.
Patient Information
- Warn patient not to instill more often than once a day in the evening. More frequent use may decrease efficacy of the medication.
- Teach patient proper technique for instilling eye drops. Wash hands; do not allow dropper to touch eye. Tilt head back, look up; pull lower eyelid down; instill drop. Close eye for 1 to 2 min and apply gentle pressure to bridge of nose. Do not rub eye.
- Advise patients who wear contact lenses to remove lenses before instilling medicine and to wait at least 15 min after instilling eye drop before inserting their lenses.
- Advise patient that if more than 1 topical ophthalmic drug is used, administer the drugs at least 5 min apart.
- Inform patient that medication may cause a gradual increase in brown pigment in the pupil, which may slowly change eye color.
- Inform patient that medication may cause eyelid skin darkening and increases in length, thickness, color, and number of eyelashes.
- Advise patient to contact the eye doctor if eye or eyelid inflammation is noted, or if eye is injured, or if eye surgery is planned.
- Remind patient that eye examinations and measurement of IOP are necessary while using this medication; advise patient to keep appointments.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
Glaucoma (Open Angle), Intraocular Hypertension
